MORE►
Astellas Pharma
[Illustration: Svetlana Brovkova via iStock]
Follow the Money: ParkHub Acquires Parking Software Startup, UpSmith Raises $3.3M, Maverick Bancshares Seeks $17M for new Fort Worth Bank, and More
by Kevin Cummings | Oct 28, 2022
In this week’s North Texas deal flow, you’ll also find news about Taysha Gene Therapies landing a $50M investment; music tech startup MAX’s Series B raise; Dallas Venture Capital’s latest investment; Tyler Technologies’ $68M acquisition of Rapid Financial Solutions; NaturalShrimp hitting the Nasdaq Capital Market; and more.
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-360x203.jpg)
by Kevin Cummings |
Oct 25, 2022
The investment by Tokyo-based Astellas Pharma gives it a 15% stake in Taysha and positions it to potentially purchase the company, according to the Dallas Morning News. The Dallas-based biotech firm's pipeline includes the "first-and-only" gene therapy in clinical development for Rett syndrome and a Phase 1/2 development of a treatment for an inherited nervous system disorder that's awaiting regulatory feedback.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
MORE►
